Ronald Cooper - Albireo Pharma President CEO, Director
| ALBODelisted Stock | USD 44.15 0.75 1.67% |
CEO
Mr. Ronald Harold Wilfred Cooper is the President, Chief Executive Officer, Director of Albireo Pharma Inc. Mr. Cooper served as President and Chief Executive Officer of Albireo Limited from July 2015 until November 2016 and has served as a director of Albireo Limited since September 2015. Prior to joining Albireo, Mr. Cooper worked for over 25 years in successive leadership roles at BristolMyers Squibb Company, a global biopharmaceutical company. Most recently, at BristolMyers Squibb Company, Mr. Cooper served as President, Europe from May 2010 until November 2015 President, Northern and Central Europe from April 2009 until April 2010 and Senior Vice President and General Manager, EU Markets from January 2008 until March 2009. Previously, Mr. Cooper held multiple senior roles in the U.S. and other countries. Mr. Cooper has served on the board of directors of Genocea Biosciences, Inc., a publicly traded biopharmaceutical company, since June 2016 since 2016.
| Age | 60 |
| Tenure | 8 years |
| Phone | 857 254 5555 |
| Web | https://www.albireopharma.com |
Albireo Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma's management efficiency ratios could be used to measure how well Albireo Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.18, which may suggest the company is not taking enough advantage from borrowing. Albireo Pharma has a current ratio of 4.4, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Albireo Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Albireo Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Albireo Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Albireo to invest in growth at high rates of return. When we think about Albireo Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | CEO Age | ||
| David Fox | Q2 Holdings | 45 | |
| LipBu Tan | Cadence Design Systems | 65 | |
| Dara Khosrowshahi | Uber Technologies | 54 | |
| Paul Hubner | Canada Goose Holdings | 61 | |
| Trish Donnelly | PVH Corp | 52 | |
| Steve Shiffman | PVH Corp | 59 | |
| Martijn Hagman | PVH Corp | 49 | |
| Fred Gehring | PVH Corp | 59 | |
| Patricia Donnelly | PVH Corp | 55 | |
| Daniel Grieder | PVH Corp | 56 | |
| ChiPing Hsu | Cadence Design Systems | 59 | |
| Matthew Flake | Q2 Holdings | 52 | |
| Cheryl Hodges | PVH Corp | 56 | |
| Patrick Goepel | Asure Software | 62 | |
| Stefan Larsson | PVH Corp | 49 | |
Management Performance
| Return On Equity | -0.93 | |||
| Return On Asset | -0.25 |
Albireo Pharma Leadership Team
Elected by the shareholders, the Albireo Pharma's board of directors comprises two types of representatives: Albireo Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Albireo. The board's role is to monitor Albireo Pharma's management team and ensure that shareholders' interests are well served. Albireo Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Albireo Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michelle Graham, Chief Officer | ||
| Peter Zorn, Senior Vice President - Corporate Development, General Counsel and Secretary | ||
| Brian Pereira, Independent Director | ||
| Kristina Torfgard, VP Head | ||
| Davey Scoon, Director | ||
| Stephanie Okey, Director | ||
| Pamela MPH, Chief Officer | ||
| Anne Klibanski, Director | ||
| Denise ScotsKnight, Director | ||
| Jason Duncan, Gen Officer | ||
| Thomas Shea, CFO, Treasurer | ||
| Pamela Stephenson, Chief Commercial Officer | ||
| Michael Gutch, Director | ||
| Joan Connolly, Chief Officer | ||
| Martha Carter, Chief Regulatory Officer | ||
| Jan Mattsson, MD Officer | ||
| David Chiswell, Chairman of the Board | ||
| Ronald Cooper, President CEO, Director | ||
| Patrick Horn, Chief Medical Officer | ||
| Simon Harford, CFO, Treasurer | ||
| Roger Jeffs, Director | ||
| Heather Preston, Director | ||
| Paresh Soni, Chief Medical Officer | ||
| PerGoran Gillberg, CoFounder Devel | ||
| Julia Brown, Independent Director |
Albireo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Albireo Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (2.29) % | |||
| Operating Margin | (2.15) % | |||
| Current Valuation | 259.98 M | |||
| Shares Outstanding | 20.74 M | |||
| Shares Owned By Insiders | 3.60 % | |||
| Shares Owned By Institutions | 96.40 % | |||
| Number Of Shares Shorted | 553.91 K | |||
| Price To Earning | (4.16) X |
Pair Trading with Albireo Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Albireo Stock
| 0.75 | BA | Boeing Earnings Call This Week | PairCorr |
| 0.59 | APAC | Stonebridge Acquisition Symbol Change | PairCorr |
| 0.45 | TRCA | Twin Ridge Capital | PairCorr |
| 0.45 | CSCO | Cisco Systems Fiscal Quarter End 30th of April 2024 | PairCorr |
| 0.43 | LION | Lionheart III Corp | PairCorr |
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Albireo Stock
If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |